Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Retained Earnings of $46.5 billion for Q2 2026, up 0.8% year-over-year from $46.1 billion in Q2 2025, and little changed quarter-over-quarter from $46.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Retained Earnings (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Retained Earnings for 18 consecutive years, with $46.5 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 0.8% year-over-year to $46.5 billion; the TTM figure through Jun 2026 stood at $46.5 billion (up 0.8% YoY), while the FY2025 annual figure was $46.4 billion, up 0.79% from the prior year.
- Retained Earnings held at $46.5 billion in Q2 2026 per CELG-RI's latest filing, from $46.4 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $46.5 billion in Q2 2026 and bottomed at $43.8 billion in Q1 2022.
- Historically, Retained Earnings has averaged $45.6 billion across 5 years, with a median of $45.7 billion in 2023.
- On a YoY basis, Retained Earnings climbed as much as 3.16% in 2023 and fell as far as 0.24% in 2023.
- Bristol Myers Squibb's Retained Earnings stood at $45.2 billion in 2022, then increased by 1.15% to $45.7 billion in 2023, then increased by 0.74% to $46.0 billion in 2024, then increased by 0.79% to $46.4 billion in 2025, then advanced by 0.25% to $46.5 billion in 2026.
- Business Quant data shows CELG-RI's Retained Earnings at $46.5 billion in Q2 2026, $46.4 billion in Q1 2026, and $46.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 46.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.50 Bn |
| Mar 31, 2026 | 46.37 Bn |
| Dec 31, 2025 | 16.90 Bn |
| Sep 30, 2025 | -1.51 Bn |
| Jun 30, 2025 | 16.15 Bn |
| Mar 31, 2025 | 16.11 Bn |
| Dec 31, 2024 | 46.02 Bn |
| Sep 30, 2024 | -1.47 Bn |
| Jun 30, 2024 | 16.10 Bn |
| Mar 31, 2024 | -1.40 Bn |
| Dec 31, 2023 | 28.77 Bn |
| Sep 30, 2023 | 28.22 Bn |
| Jun 30, 2023 | 45.30 Bn |
| Mar 31, 2023 | 26.57 Bn |
| Dec 31, 2022 | 25.50 Bn |
| Sep 30, 2022 | 24.68 Bn |
| Jun 30, 2022 | 24.22 Bn |
| Mar 31, 2022 | 23.95 Bn |
| Dec 31, 2021 | -1.27 Bn |
| Sep 30, 2021 | 22.63 Bn |